z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response

Massimiliano Monticone, Emanuela Biollo, Andrea Fabiano, Marina Fabbi, Antonio Daga, Francesco Romeo, Massimo Maffei, Alice Melotti, Walter Giaretti, Giorgio Corte, Patrizio Castagnola

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

γ-secretase inhibitors have been proposed as drugs able to kill cancer cells by targeting the NOTCH pathway. Here, we investigated two of such inhibitors, the Benzyloxicarbonyl-Leu-Leu-Nle-CHO (LLNle) and the N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), to assess whether they were effective in killing human glioblastoma tumor-initiating cells (GBM TIC) in vitro. We found that only LLNle was able at the micromolar range to induce the death of GBM TICs by apoptosis. To determine the cellular processes that were activated in GBM TICs by treatment with LLNle, we analyzed the amount of the NOTCH intracellular domain and the gene expression profiles following treatment with LLNle, DAPT, and DMSO (vehicle). We found that LLNIe, beside inhibiting the generation of the NOTCH intracellular domain, also induces proteasome inhibition, proteolytic stress, and mitotic arrest in these cells by repressing genes required for DNA synthesis and mitotic progression and by activating genes acting as mitotic inhibitors. DNA content flow cytometry clearly showed that cells treated with LLNle undergo arrest in the G2-M phases of the cell cycle. We also found that DAPT and L-685,458, another selective Notch inhibitor, were unable to kill GBM TICs, whereas lactacystin, a pure proteasome inhibitor, was effective although at a much less extent than LLNle. These data show that LLNle kills GBM TIC cells by inhibiting the proteasome activity. We suggest that LLNle, being able to target two relevant pathways for GBM TIC survival, may have a potential therapeutic value that deserves further investigation in animal models.

Original languageEnglish
Pages (from-to)1822-1834
Number of pages13
JournalMolecular Cancer Research
Volume7
Issue number11
DOIs
Publication statusPublished - Nov 2009

Fingerprint

leucylleucine
Neoplastic Stem Cells
Proteasome Endopeptidase Complex
Glioblastoma
Apoptosis
L 685458
Amyloid Precursor Protein Secretases
Proteasome Inhibitors
G2 Phase
DNA
Dimethyl Sulfoxide
Transcriptome
Cell Division
Genes
Cell Survival
Cell Cycle
Flow Cytometry
Animal Models

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response. / Monticone, Massimiliano; Biollo, Emanuela; Fabiano, Andrea; Fabbi, Marina; Daga, Antonio; Romeo, Francesco; Maffei, Massimo; Melotti, Alice; Giaretti, Walter; Corte, Giorgio; Castagnola, Patrizio.

In: Molecular Cancer Research, Vol. 7, No. 11, 11.2009, p. 1822-1834.

Research output: Contribution to journalArticle

Monticone, Massimiliano ; Biollo, Emanuela ; Fabiano, Andrea ; Fabbi, Marina ; Daga, Antonio ; Romeo, Francesco ; Maffei, Massimo ; Melotti, Alice ; Giaretti, Walter ; Corte, Giorgio ; Castagnola, Patrizio. / z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response. In: Molecular Cancer Research. 2009 ; Vol. 7, No. 11. pp. 1822-1834.
@article{d7309cfea55842e086038a100a0546a3,
title = "z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response",
abstract = "γ-secretase inhibitors have been proposed as drugs able to kill cancer cells by targeting the NOTCH pathway. Here, we investigated two of such inhibitors, the Benzyloxicarbonyl-Leu-Leu-Nle-CHO (LLNle) and the N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), to assess whether they were effective in killing human glioblastoma tumor-initiating cells (GBM TIC) in vitro. We found that only LLNle was able at the micromolar range to induce the death of GBM TICs by apoptosis. To determine the cellular processes that were activated in GBM TICs by treatment with LLNle, we analyzed the amount of the NOTCH intracellular domain and the gene expression profiles following treatment with LLNle, DAPT, and DMSO (vehicle). We found that LLNIe, beside inhibiting the generation of the NOTCH intracellular domain, also induces proteasome inhibition, proteolytic stress, and mitotic arrest in these cells by repressing genes required for DNA synthesis and mitotic progression and by activating genes acting as mitotic inhibitors. DNA content flow cytometry clearly showed that cells treated with LLNle undergo arrest in the G2-M phases of the cell cycle. We also found that DAPT and L-685,458, another selective Notch inhibitor, were unable to kill GBM TICs, whereas lactacystin, a pure proteasome inhibitor, was effective although at a much less extent than LLNle. These data show that LLNle kills GBM TIC cells by inhibiting the proteasome activity. We suggest that LLNle, being able to target two relevant pathways for GBM TIC survival, may have a potential therapeutic value that deserves further investigation in animal models.",
author = "Massimiliano Monticone and Emanuela Biollo and Andrea Fabiano and Marina Fabbi and Antonio Daga and Francesco Romeo and Massimo Maffei and Alice Melotti and Walter Giaretti and Giorgio Corte and Patrizio Castagnola",
year = "2009",
month = "11",
doi = "10.1158/1541-7786.MCR-09-0225",
language = "English",
volume = "7",
pages = "1822--1834",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response

AU - Monticone, Massimiliano

AU - Biollo, Emanuela

AU - Fabiano, Andrea

AU - Fabbi, Marina

AU - Daga, Antonio

AU - Romeo, Francesco

AU - Maffei, Massimo

AU - Melotti, Alice

AU - Giaretti, Walter

AU - Corte, Giorgio

AU - Castagnola, Patrizio

PY - 2009/11

Y1 - 2009/11

N2 - γ-secretase inhibitors have been proposed as drugs able to kill cancer cells by targeting the NOTCH pathway. Here, we investigated two of such inhibitors, the Benzyloxicarbonyl-Leu-Leu-Nle-CHO (LLNle) and the N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), to assess whether they were effective in killing human glioblastoma tumor-initiating cells (GBM TIC) in vitro. We found that only LLNle was able at the micromolar range to induce the death of GBM TICs by apoptosis. To determine the cellular processes that were activated in GBM TICs by treatment with LLNle, we analyzed the amount of the NOTCH intracellular domain and the gene expression profiles following treatment with LLNle, DAPT, and DMSO (vehicle). We found that LLNIe, beside inhibiting the generation of the NOTCH intracellular domain, also induces proteasome inhibition, proteolytic stress, and mitotic arrest in these cells by repressing genes required for DNA synthesis and mitotic progression and by activating genes acting as mitotic inhibitors. DNA content flow cytometry clearly showed that cells treated with LLNle undergo arrest in the G2-M phases of the cell cycle. We also found that DAPT and L-685,458, another selective Notch inhibitor, were unable to kill GBM TICs, whereas lactacystin, a pure proteasome inhibitor, was effective although at a much less extent than LLNle. These data show that LLNle kills GBM TIC cells by inhibiting the proteasome activity. We suggest that LLNle, being able to target two relevant pathways for GBM TIC survival, may have a potential therapeutic value that deserves further investigation in animal models.

AB - γ-secretase inhibitors have been proposed as drugs able to kill cancer cells by targeting the NOTCH pathway. Here, we investigated two of such inhibitors, the Benzyloxicarbonyl-Leu-Leu-Nle-CHO (LLNle) and the N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), to assess whether they were effective in killing human glioblastoma tumor-initiating cells (GBM TIC) in vitro. We found that only LLNle was able at the micromolar range to induce the death of GBM TICs by apoptosis. To determine the cellular processes that were activated in GBM TICs by treatment with LLNle, we analyzed the amount of the NOTCH intracellular domain and the gene expression profiles following treatment with LLNle, DAPT, and DMSO (vehicle). We found that LLNIe, beside inhibiting the generation of the NOTCH intracellular domain, also induces proteasome inhibition, proteolytic stress, and mitotic arrest in these cells by repressing genes required for DNA synthesis and mitotic progression and by activating genes acting as mitotic inhibitors. DNA content flow cytometry clearly showed that cells treated with LLNle undergo arrest in the G2-M phases of the cell cycle. We also found that DAPT and L-685,458, another selective Notch inhibitor, were unable to kill GBM TICs, whereas lactacystin, a pure proteasome inhibitor, was effective although at a much less extent than LLNle. These data show that LLNle kills GBM TIC cells by inhibiting the proteasome activity. We suggest that LLNle, being able to target two relevant pathways for GBM TIC survival, may have a potential therapeutic value that deserves further investigation in animal models.

UR - http://www.scopus.com/inward/record.url?scp=72449168031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449168031&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-09-0225

DO - 10.1158/1541-7786.MCR-09-0225

M3 - Article

C2 - 19861404

AN - SCOPUS:72449168031

VL - 7

SP - 1822

EP - 1834

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 11

ER -